Sienna Biopharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SNNAQ research report →
Price Chart
About the company
Sienna Biopharmaceuticals, Inc. was a clinical-stage biopharmaceutical firm dedicated to discovering and advancing pharmaceutical treatments across diverse therapeutic fields. Its primary focus involved crafting therapies within immunology and inflammation, specifically targeting particular tissue pathways, notably in the skin.
- CEO
- David E. I. Pyott
- IPO
- 2017
- Employees
- 13
- HQ
- Westlake Village, CA, US
Get TickerSpark's AI analysis on SNNAQ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.09K
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.24
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -59.78%
- ROIC
- -92.02%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-157,000-30.8%
- Op Income
- $-76,498,000
- Net Income
- $-73,314,000-45.0%
- EPS
- $-3.59+30.8%
- OCF Growth
- -50.2%
- FCF Growth
- -49.3%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -2.61
- RSI (14)
- 52
- Avg Volume
- 811
No earnings-call transcripts are available for SNNAQ yet.
- Free Float
- 99.5%
- Shares Outstanding
- 30.91M
- Float Shares
- 30.76M
Our SNNAQ coverage
Recent articles, reports, and earnings notes.
No research on SNNAQ yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SNNAQ report →Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.